ALKS Share Price

Open 56.04 Change Price %
High 56.43 1 Day 0.25 0.45
Low 55.65 1 Week 0.62 1.12
Close 56.08 1 Month -0.68 -1.20
Volume 758418 1 Year -4.34 -7.18
52 Week High 60.74
52 Week Low 27.14
ALKS Important Levels
Resistance 2 56.80
Resistance 1 56.51
Pivot 56.05
Support 1 55.65
Support 2 55.36
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DRYS 1.01 -36.48%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ACAS 17.99 0.39%
MU 21.71 -2.73%
More..
NASDAQ USA Top Gainers Stocks
BGMD 0.07 133.33%
LOCM 0.09 50.00%
NFEC 1.28 40.66%
BASI 0.90 28.57%
URRE 2.68 27.62%
QKLS 0.14 27.27%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
GRVY 20.96 23.15%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
AMCF 0.03 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

Alkermes plc (NASDAQ: ALKS)

ALKS Technical Analysis 2
As on 19th Jan 2017 ALKS Share Price closed @ 56.08 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 45.92 & Sell for SHORT-TERM with Stoploss of 56.48 we also expect STOCK to react on Following IMPORTANT LEVELS.
ALKS Target for January
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
ALKS Other Details
Segment EQ
Market Capital 2719078400.00
Sector Healthcare
Industry Drug Delivery
Offical website http://www.alkermes.com
ALKS Address
ALKS
Connaught House
1 Burlington Road
Dublin, 4
Ireland
Phone: 353 1 772 8000
ALKS Latest News
Alkermes PLC (ALKS) CMO Elliot Ehrich Sells 11983 Shares   The Cerbat Gem   - 19th Jan 17
The Quantbot Technologies LP Boosts Stake in Alkermes PLC (ALKS)   DailyQuint   - 18th Jan 17
Alkermes PLC (ALKS) Insider Sells $33148.50 in Stock   Sports Perspectives   - 13th Jan 17
Alkermes plc (ALKS) Moves Lower on Volume Spike for January 11   Equities.com   - 12th Jan 17
Alkermes Plc (NASDAQ:ALKS) Heffx Trading Outlook   Live Trading News   - 09th Jan 17
Alkermes PLC: Sales Rise, Losses Fall, and the Pipeline Moves Forward   Motley Fool   - 08th Nov 16
Alkermes plc Reports Third Quarter 2016 Financial Results   Business Wire (press release)   - 02nd Nov 16
Why Alkermes PLC Skyrocketed Today   Motley Fool   - 21st Oct 16
Alkermes plc Reports Second Quarter 2016 Financial Results   Business Wire (press release)   - 28th Jul 16
Alkermes plc Reports Financial Results for the Year Ended Dec. 31, 2015 and ...   Business Wire (press release)   - 25th Feb 16
Interactive Technical Analysis Chart Alkermes plc ( ALKS NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Alkermes plc
ALKS Business Profile
Alkermes Public Limited Company, incorporated on May 4, 2011, is an integrated, global biopharmaceutical company. The Company has a portfolio of more than 20 commercial drug products and a clinical pipeline of product candidates that address central nervous system (CNS) disorders such as addiction, schizophrenia and depression. The Company manufactures RISPERDAL CONSTA, VIVITROL and polymer for BYDUREON in its Wilmington, Ohio facility. The Company operates PERDAL CONSTA lines and one VIVITROL line at commercial scale. The Company manufactures AMPYRA/FAMPYRA, RAPAMUNE and other products in its Athlone, Ireland facility. It manufactures FOCALIN XR, RITALIN LA, AVINZA, VERAPAMIL and other products in its Gainesville, Georgia facility. The Company’s RISPERDAL CONSTA (risperidone long-acting injection) and INVEGA SUSTENNA/XEPLION (paliperidone palmitate extended-release injectable suspension) are long-acting atypical antipsychotics that incorporate its technologies. RISPERDAL CONSTA uses its polymer-based microsphere injectable extended-release technology to deliver and maintain therapeutic medication levels in the body through just one injection every two weeks. RISPERDAL CONSTA is manufactured by the Company and is marketed and sold by Ortho-McNeil-Janssen Pharmaceuticals, Inc. and Janssen Pharmaceutica International, a division of Cilag International AG (Janssen) around the globe. INVEGA SUSTENNA uses its nanoparticle injectable extended-release technology to increase the rate of dissolution and enable the formulation of an aqueous suspension for once-monthly intramuscular administration.